Newsfeeds - Spark Newswire

1 minute read

Roche, Exelixis Report Second Flop Out Of Three Trials Evaluating Cabozantinib/Atezolizumab Combo

Today, 5:19 AM

Exelixis Inc (NASDAQ:EXEL) announced that the phase 3 CONTACT-03 study did not meet its primary endpoint of progression-free survival (PFS). CONTACT-03 is…

EXEL

1 minute read

Exelixis’ Phase 3 CONTACT-03 Study Did Not Meet Its Primary Endpoint Of Progression-Free Survival; Shares Fall

By Benzinga Newsdesk

Today, 5:19 AM

CONTACT-03 evaluated cabozantinib plus atezolizumab versus cabozantinib for locally advanced or metastatic clear cell or non-clear cell (papillary or unclassified only) renal cell carcinoma (RCC) who progressed during

EXEL

1 minute read

EF Hutton Maintains Buy on Exelixis, Maintains $24 Price Target

By Benzinga Newsdesk

Today, 5:19 AM

EF Hutton analyst Michael King maintains Exelixis (NASDAQ:EXEL) with a Buy and maintains $24 price target.

EXEL

5 minute read

Opdivo In Combination With CABOMETYX Shows Durable Survival With Over Three Years Of Follow-Up In The CheckMate -9ER Trial In First-Line Advanced Renal Cell Carcinoma

By Happy Mohamed

Today, 5:19 AM

Data to be featured at ASCO GU 2023 demonstrate continued overall survival, progression-free survival and objective response rate benefits with Opdivo in combination with CABOMETYX compared to

BMY

1 minute read

Piper Sandler Maintains Overweight on Exelixis, Maintains $32 Price Target

By Benzinga Newsdesk

Today, 5:19 AM

Piper Sandler analyst Alexander Goldfarb maintains Exelixis (NASDAQ:EXEL) with a Overweight and maintains $32 price target.

EXEL

9 minute read

Earnings

Earnings Scheduled For February 7, 2023

By Benzinga Insights

Today, 5:19 AM

Companies Reporting Before The Bell • BP (NYSE:BP) is likely to report quarterly earnings at $1.67 per share on revenue of $53.79 billion.

AAT

1 minute read

Exelixis’ Patent Decision In Line With Expectations, But Analysts Say Stock Overhang Could Continue

By Vandana Singh

Today, 5:19 AM

Exelixis Inc (NASDAQ:EXEL) announced that the U.S. District Court for the District of Delaware ruled in its favor, rejecting MSN…

EXEL

2 minute read

Reported Late Thursday, Exelixis Announces Update On Patent Litigation With MSN Laboratories; U.S. District Court For The District Of Delaware Ruled In Exelixis’ Favor, Rejecting Msn’s Challenge To The Cabozantinib Compound Patent

By Benzinga Newsdesk

Today, 5:19 AM

Exelixis, Inc. (NASDAQ:EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) v. MSN Laboratories Private Limited et al. (MSN), Action No. 19-2017 (Consolidated), the U.S. District Court for

EXEL